Cellistem®OA is an allogeneic cell therapy based on the expansion of a subpopulation of umbilical cord tissue mesenchymal cells (UC-MSCs), with unique characteristics for the treatment of osteoarthritis.

Applied intra-articularly in patients with mild or moderate knee osteoarthritis

It has been shown to improve the quality of life of patients, since it reduces their pain and increases their functionality due to the reduction of stiffness in the knee by more than 80% compared to the current standard treatment with Hyaluronic Acid

Safety and efficacy confirmed by phase I / IIa clinical study

More than 500 patients have been treated with Cellistem®OA in Chile and today part of the manufacturing has been transferred to the United States to comply with the FDA requirements to start Phase IIb studies in that country

Abstract Lines _edited.jpg
Abstract Lines _edited.jpg

Technology Readiness Level (TRL)